These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9589016)

  • 1. Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
    Chapple CR
    Br J Urol; 1998 Mar; 81 Suppl 1():34-47; discussion 64-6. PubMed ID: 9589016
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alpha blockers in the treatment of benign hyperplasia of the prostate].
    Gómez Sancha F; Fernández Arjona M; Peinado Ibarra F; Fernández Borrell A; Mínguez Martínez R; Pereira Sanz I
    Rev Clin Esp; 1997 May; 197(5):358-62. PubMed ID: 9280971
    [No Abstract]   [Full Text] [Related]  

  • 3. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
    Chapple CR
    Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
    Beduschi MC; Beduschi R; Oesterling JE
    Urology; 1998 Jun; 51(6):861-72. PubMed ID: 9609620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
    Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
    J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
    Doggrell SA
    Expert Opin Pharmacother; 2004 May; 5(5):1209-11. PubMed ID: 15155119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacologic treatment of benign prostatic hyperplasia].
    Romics I
    Orv Hetil; 2003 Sep; 144(37):1809-14. PubMed ID: 14596018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
    Bar-Yosef Y; Mabjeesh NJ; Laufer M; Neulander EZ; Kaver I; Matzkin H
    Harefuah; 2008 Jun; 147(6):514-9, 574. PubMed ID: 18693628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical therapy for benign prostatic hyperplasia: a review of the literature.
    Clifford GM; Farmer RD
    Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    Kyprianou N
    J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
    Jansen DJ; Resch ND; Hoffman RM
    Am J Health Syst Pharm; 1999 Jul; 56(13):1351. PubMed ID: 10683137
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
    Dutkiewics S
    Int Urol Nephrol; 2001; 32(3):423-32. PubMed ID: 11583366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are all alpha-blockers created the same?
    Irani J
    Eur Urol; 2006 Mar; 49(3):420-2. PubMed ID: 16413662
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison of different drugs on the treatment of benign prostate hyperplasia].
    Li NC; Wu SL; Jin J; Qiu SP; Kong CZ; Song YS; Ye ZQ; Sun G; Sun YH; Sun YC; Wang XF; Na YQ
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):947-50. PubMed ID: 17961376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients.
    Suzuki H
    Br J Urol; 1998 Mar; 81 Suppl 1():51-5. PubMed ID: 9589018
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparative evaluation of the efficacy of using terazosin and tamsulosin in patients with benign prostatic hyperplasia].
    Lopatkin NA; Sivkov AV; Surikov VN; Egorov AA
    Urologiia; 2002; (5 Suppl):3-12. PubMed ID: 12518668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
    Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.